Pfizer reported first-quarter earnings that exceeded Wall Street expectations, leading to a slight increase in its stock price during premarket trading. The company also reaffirmed its financial guidance for the full year 2026, signaling confidence in its ongoing performance. This positive earnings report may boost investor confidence and influence Pfizer's stock movement in the near term.
Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune re...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
